| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/31/2012 | CA2463989C Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
| 01/31/2012 | CA2391952C Inhibitors of histone deacetylase |
| 01/31/2012 | CA2380216C Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 01/31/2012 | CA2362908C Kit for radiolabeling proteins with yttrium-90 |
| 01/31/2012 | CA2226087C Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
| 01/26/2012 | WO2012012809A2 APPLICATION OF β-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT |
| 01/26/2012 | WO2012012772A2 Drug eluting hydrogels for catheter delivery |
| 01/26/2012 | WO2012012710A2 Radiation sensitization agents for prostate cancer |
| 01/26/2012 | WO2012012619A1 Protein kinase c inhibitors and uses thereof |
| 01/26/2012 | WO2012012454A1 Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan |
| 01/26/2012 | WO2012012448A1 Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| 01/26/2012 | WO2012012404A1 Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| 01/26/2012 | WO2012012370A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
| 01/26/2012 | WO2012012305A2 Combination therapy using a ruthenium complex |
| 01/26/2012 | WO2012012304A2 Method of treating refractory cancer |
| 01/26/2012 | WO2012012300A2 Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| 01/26/2012 | WO2012012278A2 Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| 01/26/2012 | WO2012011952A2 Copy number variant-dependent genes as diagnostic tools, predictive biomarkers and therapeutic targets |
| 01/26/2012 | WO2012011875A1 Compounds for photodynamic therapy |
| 01/26/2012 | WO2012011840A1 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same |
| 01/26/2012 | WO2012011836A1 The new stable polyethylene glycol conjugate of interferon alpha, represented by one positional isomer |
| 01/26/2012 | WO2012011777A2 Kit for diagnosing colorectal cancer and pharmaceutical composition for prevention or treatment of colorectal cancer |
| 01/26/2012 | WO2012011741A2 Novel fusarisetin compounds, and use thereof |
| 01/26/2012 | WO2012011591A1 Fused heterocyclic compound and application thereof |
| 01/26/2012 | WO2012011314A1 Benzofuranone compound and pharmaceutical composition containing same |
| 01/26/2012 | WO2012010826A1 Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them |
| 01/26/2012 | WO2012010768A1 Method for preparing an extract, and extract for treating cancer |
| 01/26/2012 | WO2012010704A1 New aminopyrazoloquinazolines |
| 01/26/2012 | WO2012010696A1 Methods for cancer management targeting co-029 |
| 01/26/2012 | WO2012010675A2 Bhlh proteins and their use as drugs |
| 01/26/2012 | WO2012010616A1 Medicaments based on dinuclear arene ruthenium complexes comprising bridging thiolato, selenolato or alkoxo ligands |
| 01/26/2012 | WO2012010606A1 Hexacyclic polyketides as kinase inhibitors |
| 01/26/2012 | WO2012010555A1 Tricyclic lactones for treatment of cancer |
| 01/26/2012 | WO2012010287A1 Tubulysin analogues |
| 01/26/2012 | WO2012010103A1 Aptamer, method of preparing same and use of same |
| 01/26/2012 | WO2012010091A1 Optically pure quinazoline compound |
| 01/26/2012 | WO2012010088A1 Optically pure quinazoline compounds |
| 01/26/2012 | WO2011151786A3 Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer |
| 01/26/2012 | WO2011150517A3 Xyxin fragment biomarker for diagnosis of colon cancer |
| 01/26/2012 | WO2011150457A3 Haematopoietic-prostaglandin d2 synthase inhibitors |
| 01/26/2012 | WO2011143280A3 Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling |
| 01/26/2012 | WO2011139843A3 Multi-sirna compositions for reducing gene expression |
| 01/26/2012 | WO2011139842A3 Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof |
| 01/26/2012 | WO2011127406A3 Acridines as inhibitors of haspin and dyrk kinases |
| 01/26/2012 | WO2011100295A3 Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase |
| 01/26/2012 | WO2010142007A8 Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals |
| 01/26/2012 | US20120023600 Compositions and methods of use for antibodies of dickkopf-1 |
| 01/26/2012 | US20120022236 Recombinant Anti-VLA4 Antibody Molecules |
| 01/26/2012 | US20120022154 N-hydroxy c29-amide derivatives of oleandrane |
| 01/26/2012 | US20120022153 Tricyclic condensed heterocyclic compound, process of producing same, and use thereof |
| 01/26/2012 | US20120022150 Treatment and prevention of benign pigmented moles (naevi) using artemisinine and the derivatives thereof |
| 01/26/2012 | US20120022148 Curcuminoids in Combination Docetaxel for the Treatment of Cancer and Tumour Metastasis |
| 01/26/2012 | US20120022147 2, 6 xylidine derivatives for the treatment of pain |
| 01/26/2012 | US20120022140 Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel |
| 01/26/2012 | US20120022139 Short Interfering Ribonucleic Acid (siRNA) for Oral Administration |
| 01/26/2012 | US20120022138 Means for inhibiting the expression of ang2 |
| 01/26/2012 | US20120022132 Compositions and methods for inhibiting expression of mutant egfr gene |
| 01/26/2012 | US20120022131 Breast cancer related gene rqcd1 |
| 01/26/2012 | US20120022128 PKIB and NAALADL2 for Target Genes of Prostate Cancer Therapy and Diagnosis |
| 01/26/2012 | US20120022121 Indoles, derivatives and analogs thereof and uses therefor |
| 01/26/2012 | US20120022119 Heterocyclic antagonists of prostaglandin d2 receptors |
| 01/26/2012 | US20120022118 Compounds for the treatment of proliferative disorders |
| 01/26/2012 | US20120022116 Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| 01/26/2012 | US20120022115 Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases |
| 01/26/2012 | US20120022106 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 01/26/2012 | US20120022097 Compositions and Methods for Treating Cancer |
| 01/26/2012 | US20120022092 Protein kinase c inhibitors and uses thereof |
| 01/26/2012 | US20120022088 Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer |
| 01/26/2012 | US20120022083 Small molecule modulators of cell adhesion |
| 01/26/2012 | US20120022082 Pyrazine derivatives |
| 01/26/2012 | US20120022080 Plasminogen Activator Inhibitor-1 Inhibitor |
| 01/26/2012 | US20120022076 Derivatives of n-(arylamino)sulfonamides as inhibitors of mek |
| 01/26/2012 | US20120022070 Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use |
| 01/26/2012 | US20120022068 NOVEL HETEROCYCLIC NF-kB INHIBITORS |
| 01/26/2012 | US20120022065 C-Met Modulators and Method of Use |
| 01/26/2012 | US20120022060 Tricyclic Azaindoles |
| 01/26/2012 | US20120022052 Small molecule inhibitors of kynurenine-3-monooxygenase |
| 01/26/2012 | US20120022048 Anti-proliferative substituted pyrazolo[3,4-d]pyrimidines derivatives (SPP) to inhibit immune activation, virus replication and tumor growth |
| 01/26/2012 | US20120022036 Method of treating osteoporosis |
| 01/26/2012 | US20120022035 Polymorphic and Amorphous Salt Forms of Squalamine Dilactate |
| 01/26/2012 | US20120022026 Method of treating cancer |
| 01/26/2012 | US20120022023 Hydraulic Cements, Methods and Products |
| 01/26/2012 | US20120022016 Compounds and methods for selectively targeting tumor-associated mucins |
| 01/26/2012 | US20120022015 Method of treatment and supplement |
| 01/26/2012 | US20120022011 Hsp90 inhibitors with modified toxicity |
| 01/26/2012 | US20120022010 Use of flavonoids to increase the bioavailability of hesperetin |
| 01/26/2012 | US20120022001 Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle |
| 01/26/2012 | US20120022000 Use of a peptide in the treatment or prevention of metastasis |
| 01/26/2012 | US20120021999 Pro-apoptotic peptides |
| 01/26/2012 | US20120021998 Cancer Diagnosis and Treatment Methods of Use |
| 01/26/2012 | US20120021997 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| 01/26/2012 | US20120021996 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| 01/26/2012 | US20120021995 Polypeptides that Bind TRAIL-R1 and TRAIL-R2 |
| 01/26/2012 | US20120021994 Novel cancer antigen eef2 |
| 01/26/2012 | US20120021993 Protein scaffold library based on kringle domain structure and uses thereof |
| 01/26/2012 | US20120021987 Mucin 3 EGF-Like Domains |
| 01/26/2012 | US20120021983 Compositions and methods for diagnosis and prognosis of cancer and progression, and for screening anti-cancer agents |
| 01/26/2012 | US20120021974 Novel inhibitor of angiogenesis |
| 01/26/2012 | US20120021973 Peptides for Treatment of Obesity |
| 01/26/2012 | US20120021470 Chimeric PUFA Polyketide Synthase Systems and Uses Thereof |